Biotie signs an LP market making agreement with Nordea
(Thomson Reuters ONE) - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE September 22, 2009at 10 a.m.Biotie signs an LP market making agreement with NordeaBiotie Therapies ("Biotie") and Nordea Bank Finland Plc ("Nordea")have concluded a market making agreement, which fulfils therequirements of NASDAQ OMX Helsinki Ltd's Liquidity Providing (LP)operations. The market making agreement aims at increasing theshare's liquidity and decreasing the share price volatility thusfacilitating trading.According to the agreement, Nordea will provide Biotie's share withbids and offers so that the maximum spread is 4% calculated from thebid quotation. Bids or offers include at least 4,000 shares and thevalue of the shares must correspond to at least 4,000 euros.Nordea undertakes to submit bids and offers for Biotie's share on theofficial list in the trading system of NASDAQ OMX Helsinki on eachtrading day for at least 85 per cent of the time of continuoustrading, at the opening and closing call of the trading day and inthe auction procedures applicable to the share during a trading day.The market making in accordance with the agreement will begin onSeptember 24, 2009. After a 6-month term, the market making agreementis valid until further notice. The term of notice of the agreement isone month.Turku, September 22, 2009Biotie Therapies Corp.Timo VeromaaPresident and CEOFor further information, please contact:Virve Nurmi, Investor Relations Managertel. +358 2 274 8911, e-mail: virve.nurmi(at)biotie.comwww.biotie.comDistribution:NASDAQ OMX Helsinki LtdMain Mediawww.biotie.comBiotie Therapies Corp.Biotie is a drug discovery and development company focused on centralnervous system and inflammatory diseases. It has a broad range ofinnovative small molecule and biological drug candidates at differentstages of clinical and pre-clinical development. Biotie's productsaddress diseases with high unmet medical need and significant marketpotential, including addiction and psychotic disorders, rheumatoidarthritis, psoriasis and chronic obstructive pulmonary disease(COPD). The most advanced product, nalmefene for alcohol dependence,is currently in phase III clinical development by licensing partnerH. Lundbeck A/S.The commercial value of the pipeline has been demonstrated throughexisting alliances with top-tier global pharmaceutical companies suchas Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finlandand Radebeul, Germany.Biotie shares are listed on NASDAQ OMX Helsinki Ltd.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 22.09.2009 - 09:00 Uhr
Sprache: Deutsch
News-ID 6068
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 377 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotie signs an LP market making agreement with Nordea"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
